Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Balmaña

Showing results (1-10 of 193) with videos related to

Pageof 20
Sort By:
British Journal of Cancer|December 17, 2015
PARP inhibitors in ovarian cancerDavid Cibula, Judith Balmaña
Medicina Clinica|May 16, 2009
[Predictive models for identification of germline mutation carriers in Lynch syndrome]Isela Quispe, Judith Balmaña
Journal of the National Cancer Institute|August 29, 2015
BRIP1 as an ovarian cancer susceptibility gene: ready for the clinic?Judith Balmaña, Susan M Domchek
Cancer|April 22, 2006
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumorsEduardo Vilar, Judith Balmaña, Eloy Espín
Familial Cancer|April 5, 2013
Prediction models in Lynch syndromeFay Kastrinos, Judith Balmaña, Sapna Syngal
Familial Cancer|November 27, 2009
Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testingOrland Diez, Sara Gutiérrez-Enríquez, Judith Balmaña
ESMO Open|June 25, 2019
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?Benedetta Pellegrino, Joaquin Mateo, Violeta Serra, et al.
Tumori|July 30, 2015
Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive reviewElena Aguirre, Begoña Graña, Miguel Boudet, et al.
The American Journal of Gastroenterology|March 16, 2007
Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposisFay Kastrinos, Elena M Stoffel, Judith Balmaña, et al.
Breast Cancer Research and Treatment|April 27, 2007
Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?Sara Gutiérrez-Enríquez, Judith Balmaña, Montserrat Baiget, et al.
Pageof 20

Showing results (1-10 of 193) with videos related to

Sort By:
Pageof 20
British Journal of Cancer|December 17, 2015
PARP inhibitors in ovarian cancerDavid Cibula, Judith Balmaña
Medicina Clinica|May 16, 2009
[Predictive models for identification of germline mutation carriers in Lynch syndrome]Isela Quispe, Judith Balmaña
Journal of the National Cancer Institute|August 29, 2015
BRIP1 as an ovarian cancer susceptibility gene: ready for the clinic?Judith Balmaña, Susan M Domchek
Cancer|April 22, 2006
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumorsEduardo Vilar, Judith Balmaña, Eloy Espín
Familial Cancer|April 5, 2013
Prediction models in Lynch syndromeFay Kastrinos, Judith Balmaña, Sapna Syngal
Familial Cancer|November 27, 2009
Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testingOrland Diez, Sara Gutiérrez-Enríquez, Judith Balmaña
ESMO Open|June 25, 2019
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?Benedetta Pellegrino, Joaquin Mateo, Violeta Serra, et al.
Tumori|July 30, 2015
Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive reviewElena Aguirre, Begoña Graña, Miguel Boudet, et al.
The American Journal of Gastroenterology|March 16, 2007
Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposisFay Kastrinos, Elena M Stoffel, Judith Balmaña, et al.
Breast Cancer Research and Treatment|April 27, 2007
Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?Sara Gutiérrez-Enríquez, Judith Balmaña, Montserrat Baiget, et al.
Pageof 20